ATXIOTCPharmaceutical PreparationsFiscal year ends December 31
AVENUE THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.43+0.00 (0.00%)
Close on Oct 16, 2026
- Market cap
- $1.42M
- P/E (TTM)
- –
- Dividend yield
- –
Avenue Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 16, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Avenue Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.42M | $164.85M |
| Enterprise Value | -$525.16K | $87.06M |
| PB Ratio | 2.49 | 2.03 |
| P/TBV Ratio | 2.49 | 2.31 |
Income (trailing twelve months)
| Measure | Avenue Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$2.90M | -$21.44M |
| Net Income | -$2.78M | -$22.46M |
| EBITDA | -$2.90M | -$16.91M |
| EPS (Diluted) | -$0.85 | -$0.83 |
Returns
| Measure | Avenue Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -120.0% | -53.1% |
| Return on Assets (ROA) | -90.5% | -41.0% |
| Return on Capital Employed (ROCE) | -509.1% | -37.8% |
Growth
| Measure | Avenue Therapeutics | Industry median |
|---|---|---|
| EPS Growth (YoY) | -160.7% | -29.2% |
Balance sheet
| Measure | Avenue Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.94M | $62.42M |
| Net Cash (Debt) | $1.94M | $15.68M |
| Net Cash Per Share | $0.59 | $0.66 |
| Equity (Book Value) | $569.00K | $48.79M |
| Book Value Per Share | $0.17 | $1.36 |
| Tangible Book Value | $569.00K | $23.06M |
Financial position
| Measure | Avenue Therapeutics | Industry median |
|---|---|---|
| Quick Ratio | 1.38 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Avenue Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.38M | -$12.35M |
Efficiency
| Measure | Avenue Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.78M | -$703.34K |
| Employee Count | 1 | 74 |
Dividends and yields
| Measure | Avenue Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -196.0% | -22.7% |
| Buyback Yield | 0.00% | -0.73% |
| Shareholder Yield | 0.00% | 0.00% |
Shares
| Measure | Avenue Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 3,294,970 | 58,179,650 |
| Shares Change (YoY) | 34.3% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 2,854,360 | 49,173,100 |
| Shares Held by Insiders | 13.4% | 11.6% |
Scores
| Measure | Avenue Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -79.95 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Avenue Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.